Key Proteo is democratizing the early detection of rare but treatable genetic disorders through novel and accessible proteomic analysis. As a pioneering proteomics company, Key Proteo is initially focused on the early detection of treatable rare genetic disorders in newborns, with the goal of expanding newborn screening to identify extremely low abundance protein biomarkers that were previously undetectable. Many treatable genetic disorders are difficult to detect, but when found early, intervention can be enabled to help change the clinical course. Ultimately, our mission is to relieve suffering and save lives for patients and their families afflicted by rare but treatable genetic disorders through early screening.

Health Diagnostics

Life Sciences

Medical Devices

Key Proteo, Inc.

Key Proteo, Inc.'s headquarters in Seattle, United States

Description

People (2)

Mark Willig

Sean Sandin

Jobs